bevacizumab off-label intravitreal
Selected indexed studies
- Off-label use of intravitreal bevacizumab: A global conundrum. (Indian J Ophthalmol, 2024) [PMID:38661271]
- [Off-label use of intravitreal bevacizumab for severe retinopathy of prematurity]. (Arch Soc Esp Oftalmol, 2015) [PMID:25459682]
- Off-label use of bevacizumab for wet age-related macular degeneration in Europe. (Graefes Arch Clin Exp Ophthalmol, 2020) [PMID:31889214]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ranibizumab and bevacizumab for neovascular age-related macular degeneration. (2011) pubmed
- Off-label use of intravitreal bevacizumab: A global conundrum. (2024) pubmed
- [Off-label use of intravitreal bevacizumab for severe retinopathy of prematurity]. (2015) pubmed
- Off-label use of bevacizumab for wet age-related macular degeneration in Europe. (2020) pubmed
- Off-label intravitreal Brolucizumab in the management of central serous chorioretinopathy. (2024) pubmed
- Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy. (2026) pubmed
- Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. (2022) pubmed
- "Off-label" use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions. (2016) pubmed
- Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence? (2009) pubmed
- Off-Label Uses of Ranibizumab and Aflibercept for Age-Related Macular Degeneration in Turkey. (2023) pubmed